- Home
- MREO vs ITOS Comparison
MREO vs ITOS Comparison
Compare MREO & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MREO
- ITOS
- Stock Information
- Founded
- MREO 2015
- ITOS 2011
- Country
- MREO United Kingdom
- ITOS United States
- Employees
- MREO N/A
- ITOS N/A
- Industry
- MREO Biotechnology: Pharmaceutical Preparations
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MREO Health Care
- ITOS Health Care
- Exchange
- MREO Nasdaq
- ITOS Nasdaq
- Market Cap
- MREO 438.8M
- ITOS 446.6M
- IPO Year
- MREO N/A
- ITOS 2020
- Fundamental
- Price
- MREO $1.74
- ITOS $10.11
- Analyst Decision
- MREO Strong Buy
- ITOS Hold
- Analyst Count
- MREO 5
- ITOS 6
- Target Price
- MREO $7.20
- ITOS $10.40
- AVG Volume (30 Days)
- MREO 1.8M
- ITOS 1.6M
- Earning Date
- MREO 08-12-2025
- ITOS 08-06-2025
- Dividend Yield
- MREO N/A
- ITOS N/A
- EPS Growth
- MREO N/A
- ITOS N/A
- EPS
- MREO N/A
- ITOS N/A
- Revenue
- MREO $500,000.00
- ITOS N/A
- Revenue This Year
- MREO N/A
- ITOS N/A
- Revenue Next Year
- MREO $38.38
- ITOS N/A
- P/E Ratio
- MREO N/A
- ITOS N/A
- Revenue Growth
- MREO N/A
- ITOS 177.89
- 52 Week Low
- MREO $1.47
- ITOS $4.80
- 52 Week High
- MREO $5.02
- ITOS $18.13
- Technical
- Relative Strength Index (RSI)
- MREO 44.98
- ITOS 53.14
- Support Level
- MREO $1.64
- ITOS $10.08
- Resistance Level
- MREO $1.78
- ITOS $10.17
- Average True Range (ATR)
- MREO 0.09
- ITOS 0.04
- MACD
- MREO 0.04
- ITOS -0.02
- Stochastic Oscillator
- MREO 87.10
- ITOS 35.29
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.